mRNA vaccine for older adults to prevent RSV and hMPV
This trial tests a new mRNA vaccine designed to protect older adults against two common respiratory viruses, RSV and hMPV. It aims to see if the vaccine is safe and creates a good immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are in good general health, or have stable chronic conditions that are under control.
- You are at least 18 years old, but this study is for healthy older adults (likely 60 or older – ask the study team).
- Your weight is in a healthy range for your height (body mass index between 18.5 and 35).
- You have never had a severe allergic reaction (anaphylaxis) to any mRNA vaccine or its ingredients.
- You have not received an RSV vaccine before, and you have not been in a study with RSV or hMPV vaccines.
- You do not have a weak immune system, an autoimmune disease, or a history of certain blood or organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This study tests how your body's immune system responds to a new respiratory syncytial virus (RSV) vaccine. RSV is a common virus that causes respiratory infections, especially in older adults. The vaccine may help protect you from RSV disease.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This study tests a new RSV vaccine designed to protect adults with chronic health conditions from severe RSV disease (a respiratory infection). Researchers will monitor how safe the vaccine is and how well your immune system responds to it.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This trial tests a new vaccine (MKK900) to see if it is safe and works well in healthy adult women. It is designed to protect against RSV, a common virus that can be serious in newborns and older adults. The vaccine is being developed for use during pregnancy to pass protection to babies.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.